msgid ""
msgstr ""
"Project-Id-Version: PACKAGE VERSION\n"
-"POT-Creation-Date: 2020-06-16 01:18+0000\n"
+"POT-Creation-Date: 2020-11-02 03:50+0000\n"
"PO-Revision-Date: YEAR-MO-DA HO:MI+ZONE\n"
"Last-Translator: FULL NAME <EMAIL@ADDRESS>\n"
"Language-Team: LANGUAGE <LL@li.org>\n"
"enhancers ([Blader and coll., 2003](https://pubmed.gov/12559493)) and their "
"evolutionary conservation ([Plessy and coll., 2005](https://pubmed."
"gov/15797614)). This gave me a strong interest for whole-transcriptome "
-"analysis and technology. For that purpose, I have joined RIKEN in 2004, "
-"where have worked on high-throughput methods for **profiling promoters and "
-"inferring gene networks**, and in particular on CAGE (Cap Analysis Gene "
-"Expression)."
+"analysis and technology. For that purpose, I have worked at RIKEN in 2004–18 "
+"on high-throughput methods for **profiling promoters and inferring gene "
+"networks**, and in particular on CAGE (Cap Analysis Gene Expression)."
msgstr ""
#. type: Plain text
"gov/23180801)), combining multiple cap-enrichment steps ([Batut and coll., "
"2013](https://pubmed.gov/22936248)), benchmarking the use of locked nucleic "
"acids for template switching ([Harbers and coll., 2013](https://pubmed."
-"gov/24079827)), and reducing the number of primer artefacts and unwanted "
+"gov/24079827)), reducing the number of primer artefacts and unwanted "
"sequences generated by ribosomal RNAs using low-complexity “pseudo-random” "
"reverse-transcription primers ([Arnaud and coll., 2016](https://pubmed."
-"gov/27071605))."
+"gov/27071605)), and screening for optimal parameters of the template-"
+"switching reaction ([Poulain and coll., 2020](https://pubmed.gov/32025730))."
msgstr ""
#. type: Plain text
msgid ""
-"On April 2013, I started a new development cycle as the leader of the "
-"Genomics Miniaturization Technology Unit at RIKEN Center for Life Sciences, "
-"Division of Genomics Technology, to expand this work on single cells "
-"following a **population transcriptomics** approach ([Plessy and coll., 2013]"
-"(https://pubmed.gov/23281054)) focused on sampling the largest possible "
-"number of cells. In our ongoing developments, we have reached **single-cell "
-"and single molecule resolution** through the introduction of transposase "
-"fragmentation and unique molecular identifiers ([Poulain and coll., 2017]"
-"(https://pubmed.gov/28349422)). The protocol exists in two versions, one for "
-"FACS-isolated cells, and one for the Fluidigm C1 platform ([Kouno and coll., "
-"2019](https://pubmed.gov/30664627))."
+"In 2013–8, I lead a new development cycle at the Genomics Miniaturization "
+"Technology Unit in RIKEN's Center for Life Sciences, Division of Genomics "
+"Technology, to expand this work on single cells following a **population "
+"transcriptomics** approach ([Plessy and coll., 2013](https://pubmed."
+"gov/23281054)) focused on sampling the largest possible number of cells. In "
+"our ongoing developments, we have reached **single-cell and single molecule "
+"resolution** through the introduction of transposase fragmentation and "
+"unique molecular identifiers ([Poulain and coll., 2017](https://pubmed."
+"gov/28349422)). The protocol exists in two versions, one for FACS-isolated "
+"cells, and one for the Fluidigm C1 platform ([Kouno and coll., 2019](https://"
+"pubmed.gov/30664627))."
msgstr ""
#. type: Plain text
"(https://pubmed.gov/24904046)), and neurogenesis in the mouse olfactory "
"epithelium using single-cell CAGE and ATAC-seq techniques. In parallel with "
"this promoter-centric work, I have also explored the huge repertoire of the "
-"**T cell antigen receptors**."
+"T cell antigen receptors. I also applied the nanoCAGE technology to patient "
+"samples infected with the human papillomavirus (HPV) ([Taguchi and coll., "
+"2020](https://pubmed.gov/33093512))."
msgstr ""
#. type: Plain text
projects / source / .git / commitdiff